Cullinan Therapeutics falls 3.3% on widened losses despite earnings beat
Biotech ends 2025 with $439M cash position and multiple 2026 catalysts including CLN-978 data and zipalertinib NDA
Cullinan Therapeutics shares dropped 3.3% to $15.60 in Tuesday morning trading after the biotechnology company reported fourth-quarter results that showed a wider year-over-year loss despite beating earnings expectations.
The Cambridge, Massachusetts-based company posted a net loss of $50.7 million for the quarter ended December 31, 2025, compared with $47.6 million in the same period a year earlier. The loss per share came in at $0.77, better than the consensus estimate of $0.892, representing a 13.7% earnings beat, according to the company's earnings release.
For the full year 2025, Cullinan's net loss deepened to $219.9 million from $167.4 million in 2024. Research and development expenses reached $187.4 million for the year, while general and administrative costs totaled $54.2 million.
Despite the widening losses, investors focused on the company's robust cash position and upcoming clinical catalysts. Cullinan ended 2025 with cash, cash equivalents, short- and long-term investments totaling $439 million, which provides a runway into 2029 under its current operating plan.
"Cullinan anticipates a catalyst-rich 2026 across its pipeline," the company stated in its earnings announcement, highlighting what executives have called a "defining year" for the organization.
Key upcoming milestones include initial clinical data for CLN-978, the company's CD19xCD3 bispecific T cell engager for autoimmune diseases, expected in the second quarter. The data will focus on safety, B cell depletion, biomarker measurements, and preliminary clinical activity in patients with systemic lupus erythematosus and rheumatoid arthritis. Repeat dosing data for rheumatoid arthritis is anticipated in the third quarter.
In oncology, Cullinan's partner Taiho Pharmaceutical completed the rolling New Drug Application submission for zipalertinib in the first quarter for the treatment of patients with relapsed EGFR exon 20 insertion non-small cell lung cancer. The FDA granted zipalertinib Breakthrough Therapy Designation in 2021. Cullinan is eligible to receive up to $130 million in U.S. regulatory milestone payments and a 50/50 profit share in the United States from the partnership.
The company's CLN-049 program, a FLT3xCD3 bispecific T cell engager, recently received FDA Fast Track designation for relapsed/refractory acute myeloid leukemia. Cullinan plans to complete monotherapy dose expansion cohorts to determine a recommended Phase 2 dose by year-end 2026, with a combination study in frontline AML slated to begin in the fourth quarter.
Wall Street analysts remain bullish on the stock despite Tuesday's decline. The consensus rating stands at "Moderate Buy" to "Strong Buy" with an average price target of approximately $29.50, implying nearly 90% upside from current levels, according to MarketBeat data. Individual analyst targets range from $22 to $38.
Citigroup initiated coverage in February with a "Buy" rating and $33 price target, citing the company's robust pipeline in oncology and autoimmune diseases.
However, some investors may be concerned about the pace of cash burn. The company recorded $22.2 million in interest income during 2025, helping offset operational expenses, but the $219.9 million annual loss represents a significant depletion of the cash reserves.
Cullinan's stock has been volatile, trading within a 52-week range of $5.68 to $16.74. The shares remain above both their 50-day moving average of $12.24 and 200-day moving average of $9.15, suggesting longer-term bullish sentiment despite recent fluctuations.
The company's institutional ownership stands at 108.4%, indicating significant investor interest despite the modest market capitalization of approximately $930 million.
As Cullinan approaches what could be a pivotal year with multiple data readouts, investors will be watching closely for signs that the clinical programs can deliver results that justify the continued cash burn and support analysts' optimistic price targets.